{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:03:02Z","timestamp":1790726582232,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL164516"],"award-info":[{"award-number":["R01HL164516"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["UG3HL176627"],"award-info":[{"award-number":["UG3HL176627"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103459","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:46:12Z","timestamp":1774543572000},"page":"103459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic therapy at the end-of-life\u2014continue or stop?"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0808-8779","authenticated-orcid":false,"given":"Gerard","family":"Gurumurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naisthika","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biddy","family":"Bassam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jecko","family":"Thachil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103459_bib1","article-title":"Is pulmonary embolism a chronic disease?","volume":"25","author":"Gurumurthy","year":"2025","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.rpth.2026.103459_bib2","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"Nicholson","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.rpth.2026.103459_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36728","article-title":"Ethical aspects of physician decision-making for deprescribing among older adults with dementia","volume":"6","author":"Norton","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2026.103459_bib4","series-title":"Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism","year":"2019"},{"key":"10.1016\/j.rpth.2026.103459_bib5","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1200\/JOP.2015.004473","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"11","author":"Lyman","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.rpth.2026.103459_bib6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/jamainternmed.2021.1819","article-title":"Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life","volume":"181","author":"Ouellet","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.rpth.2026.103459_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12904-021-00786-3","article-title":"Use of antithrombotics at the end of life: an in-depth chart review study","volume":"20","author":"Huisman","year":"2021","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.rpth.2026.103459_bib8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1089\/jpm.2016.0487","article-title":"Prevalence and clinical intentions of antithrombotic therapy on discharge to hospice care","volume":"20","author":"Kowalewska","year":"2017","journal-title":"J Palliat Med"},{"key":"10.1016\/j.rpth.2026.103459_bib9","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1111\/bjh.70032","article-title":"Anti-thrombotic therapy in patients with cancer at the end of life and associated clinical outcomes: a cohort study using population-linked routinely collected data","volume":"207","author":"Aldridge","year":"2025","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103459_bib10","doi-asserted-by":"crossref","unstructured":"Kempers EK, Visser C, Geijteman ECT, Goedegebuur J, Portielje JEA, S\u00f8gaard M, et al. Discontinuation of anticoagulants and occurrence of bleeding and thromboembolic events in vitamin K antagonist users with a life-limiting disease. Thromb Haemost. In press. https:\/\/doi.org\/10.1055\/a-2524-5334.","DOI":"10.1055\/a-2524-5334"},{"key":"10.1016\/j.rpth.2026.103459_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jtha.2024.09.023","article-title":"Use of antithrombotic therapy and the risk of cardiovascular outcomes and bleeding in cancer patients at the end of life: a Danish nationwide cohort study","volume":"23","author":"S\u00f8gaard","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib13","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.rpth.2026.103459_bib15","doi-asserted-by":"crossref","first-page":"381S","DOI":"10.1378\/chest.08-0656","article-title":"Prevention of venous thromboembolism","volume":"133","author":"Geerts","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2026.103459_bib16","first-page":"325","article-title":"Pancreatic cancer and thromboembolic disease, 150 years after Trousseau","volume":"4","author":"Ansari","year":"2015","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.rpth.2026.103459_bib17","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.rpth.2026.103459_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102985","article-title":"Radiotherapy\u2014the not so insignificant contributor to cancer-associated venous thrombosis","volume":"9","author":"Gurumurthy","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7861\/clinmedicine.19-4-315","article-title":"Venous thromboembolism and palliative care","volume":"19","author":"Noble","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.rpth.2026.103459_bib20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/jth.12955","article-title":"Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis","volume":"13","author":"Schulman","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib21","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1055\/s-0039-1696659","article-title":"Treatment of cancer-associated thrombosis: beyond HOKUSAI","volume":"03","author":"Mah\u00e9","year":"2019","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2026.103459_bib22","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103459_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis\u2014rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"Van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.rpth.2026.103459_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12904-021-00809-z","article-title":"Anticoagulation for patients with mechanical heart valves at the end of life: understanding clinician attitudes and improving decision making","volume":"20","author":"Raby","year":"2021","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.rpth.2026.103459_bib26","article-title":"Are we comfortable managing oral anticoagulation at the end of life? A national survey of secondary care clinicians in the UK","volume":"25","author":"Shevlin","year":"2025","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.rpth.2026.103459_bib27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6939-13-22","article-title":"The ethical decisions UK doctors make regarding advanced cancer patients at the end of life\u2014the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study","volume":"13","author":"Sheard","year":"2012","journal-title":"BMC Med Ethics"},{"key":"10.1016\/j.rpth.2026.103459_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004663","article-title":"Shared decision-making and deprescribing to support anti-thrombotic therapy (dis)continuance for persons living with cancer in their last phase of life: a realist synthesis","volume":"22","author":"Jagosh","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.rpth.2026.103459_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12904-023-01155-y","article-title":"Accuracy of clinical predictions of prognosis at the end-of-life: evidence from routinely collected data in urgent care records","volume":"22","author":"Orlovic","year":"2023","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.rpth.2026.103459_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101195","article-title":"Prognostic evaluation in patients with advanced cancer in the last months of life: ESMO Clinical Practice Guideline","volume":"8","author":"Stone","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.rpth.2026.103459_bib31","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jpainsymman.2016.12.330","article-title":"Prognostic tools in patients with advanced cancer: a systematic review","volume":"53","author":"Simmons","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.rpth.2026.103459_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1001\/jama.289.18.2387","article-title":"Patterns of functional decline at the end of life","volume":"289","author":"Lunney","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2026.103459_bib33","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden, and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): a prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.103459_bib34","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2352-3026(18)30218-7","article-title":"Is venous thromboembolism a problem in patients with cancer in palliative care?","volume":"6","author":"Sandset","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.103459_bib35","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1136\/bmjspcare-2019-002039","article-title":"\u2018Hospice inpatient deep vein thrombosis detection (HIDDen) in advanced non-malignant diseases\u2019: a longitudinal pilot study","volume":"12","author":"White","year":"2022","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.rpth.2026.103459_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221081121","article-title":"Venous thromboembolism in patients with cancer receiving specialist palliative care","volume":"28","author":"Allende-P\u00e9rez","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.103459_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-073049","article-title":"HIDDEN2: study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care","volume":"13","author":"Kitson","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2026.103459_bib38","doi-asserted-by":"crossref","first-page":"E1198","DOI":"10.1503\/cmaj.220919","article-title":"Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study","volume":"194","author":"Chin-Yee","year":"2022","journal-title":"CMAJ"},{"key":"10.1016\/j.rpth.2026.103459_bib39","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study","volume":"15","author":"Tardy","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103459_bib40","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1089\/jpm.2024.0108","article-title":"Treatment with antithrombotics in the last year of life\u2014incidence of bleeding and side effects after deprescribing","volume":"27","author":"Frisk","year":"2024","journal-title":"J Palliat Med"},{"key":"10.1016\/j.rpth.2026.103459_bib41","first-page":"41","article-title":"Evaluation of the use of anticoagulotherapy in cancer patients in palliative care residence","volume":"4","author":"Polesello","year":"2023","journal-title":"Palliat Med Rep"},{"key":"10.1016\/j.rpth.2026.103459_bib42","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1136\/bmjspcare-2019-001804","article-title":"Management of venous thromboembolism in far-advanced cancer: current practice","volume":"12","author":"Noble","year":"2022","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.rpth.2026.103459_bib43","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamainternmed.2020.2908","article-title":"Assessment of shared decision-making for stroke prevention in patients with atrial fibrillation: a randomized clinical trial","volume":"180","author":"Kunneman","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.rpth.2026.103459_bib44","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/hematology.2024000559","article-title":"Anticoagulation at the end of life: whether, when, and how to treat","volume":"2024","author":"Parks","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.rpth.2026.103459_bib45","first-page":"71","article-title":"The development and evaluation of an oncological palliative care deprescribing guideline: the \u2018OncPal deprescribing guideline\u2019","volume":"23","author":"Lindsay","year":"2015","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rpth.2026.103459_bib46","first-page":"2933","article-title":"Deprescribing in palliative patients with cancer: a concise review of tools and guidelines","volume":"30","author":"Van Merendonk","year":"2022","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.rpth.2026.103459_bib47","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/ageing\/afaa159","article-title":"Deprescribing in older people approaching end-of-life: development and validation of STOPPFrail version 2","volume":"50","author":"Curtin","year":"2021","journal-title":"Age Ageing"},{"key":"10.1016\/j.rpth.2026.103459_bib48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.16278","article-title":"Deprescribing in older people approaching end of life: a randomized controlled trial using STOPPFrail criteria","volume":"68","author":"Curtin","year":"2020","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.rpth.2026.103459_bib49","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2023.05.008","article-title":"Towards optimal use of antithrombotic therapy of people with cancer at the end of life: a research protocol for the development and implementation of the SERENITY shared decision support tool","volume":"228","author":"Goedegebuur","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103459_bib50","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/1755-5922.12129","article-title":"Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation","volume":"33","author":"Steinberg","year":"2015","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.rpth.2026.103459_bib51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.103459_bib52","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/S0049-3848(10)70015-3","article-title":"Bleeding complications associated with anticoagulant therapy in patients with cancer","volume":"125","author":"Trujillo-Santos","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103459_bib53","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103459_bib54","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1007\/s00415-020-09775-7","article-title":"A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place","volume":"268","author":"Swan","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.rpth.2026.103459_bib55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0167-4943(01)00184-4","article-title":"Stroke prevention in atrial fibrillation: physicians\u2019 attitudes to anticoagulation in older people","volume":"33","author":"Vasishta","year":"2001","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.rpth.2026.103459_bib56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.amjmed.2012.01.033","article-title":"Risk of falls and major bleeds in patients on oral anticoagulation therapy","volume":"125","author":"Donz\u00e9","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2026.103459_bib57","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/acem.13217","article-title":"Risk of intracranial hemorrhage in ground-level fall with antiplatelet or anticoagulant agents","volume":"24","author":"Ganetsky","year":"2017","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.rpth.2026.103459_bib58","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"Khorana","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103459_bib59","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"Posch","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103459_bib60","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/0269216305pm1008oa","article-title":"Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study","volume":"19","author":"Noble","year":"2005","journal-title":"Palliat Med"},{"key":"10.1016\/j.rpth.2026.103459_bib61","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/026921639701100407","article-title":"Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin","volume":"11","author":"Johnson","year":"1997","journal-title":"Palliat Med"},{"key":"10.1016\/j.rpth.2026.103459_bib62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59\u20137939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.103459_bib63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2026.103459_bib64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/8755122516646384","article-title":"Administration of direct oral anticoagulants through enteral feeding tubes","volume":"32","author":"Peterson","year":"2016","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.rpth.2026.103459_bib65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/IJNRD.S105771","article-title":"Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations","volume":"10","author":"Lutz","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1016\/j.rpth.2026.103459_bib66","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/asheducation-2016.1.612","article-title":"Reversal of direct oral anticoagulants: a practical approach","volume":"2016","author":"Shih","year":"2016","journal-title":"Hematology"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:17:21Z","timestamp":1790723841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926001172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926001172"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103459","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic therapy at the end-of-life\u2014continue or stop?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103459"}}